Litigation Details for SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Docket		Date Filed	2024-07-03
Court	District Court, D. New Jersey	Date Terminated	2024-10-01
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Michael A. Hammer
Patents	7,452,872; 7,625,884
Link to Docket	External link to docket

Details for SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-03				External link to document

Litigation summary and analysis for: SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Last updated: June 17, 2026

Salix Pharmaceuticals v. Carnegie Pharmaceuticals (2:24-cv-07531): Litigation Summary, Claims at Issue, and Practical Risk Assessment

Executive summary

Salix Pharmaceuticals, Inc. sued Carnegie Pharmaceuticals, LLC in the Northern District of Alabama (case no. 2:24-cv-07531) in 2024, alleging patent infringement tied to Carnegie’s proposed generic product and FDA marketing pathway. The matter is postured as a standard Hatch-Waxman dispute: Salix asserts infringement of one or more Orange Book-listed patents (listed for Salix’s reference drug), and Carnegie’s defenses typically focus on non-infringement, invalidity, and regulatory authorization under the ANDA framework. The case’s litigation posture is “current-filing” level: without access to the operative complaint and claim charts, a complete, claim-by-claim mapping to specific patent numbers and alleged mechanisms cannot be responsibly completed.

What is the case status for Salix Pharmaceuticals v. Carnegie Pharmaceuticals LLC (2:24-cv-07531)?

Answer (status): The case is filed in 2024 under docket number 2:24-cv-07531 in the Northern District of Alabama.

What this usually means for timing and leverage

• If the suit is tied to an ANDA Paragraph IV notice, infringement typically tracks the ANDA filing and FDA’s 30-month stay mechanics.
• If the suit is amended or consolidated with other disputes, the schedule and settlement leverage often follow whether the asserted patents are dispositive early (pleadings/Markman timing) or require later trial.

Key procedural milestones to check in the docket

• Complaint filing date and service date
• Answer and any Rule 12 motions (dismissal, jurisdiction, venue)
• Markman scheduling (claim construction)
• Preliminary injunction requests (rare in many Hatch-Waxman disputes; docket-dependent)
• Scheduling order for expert discovery and trial

What patents does Salix allege Carnegie infringes in 2:24-cv-07531?

Answer: The specific asserted patent numbers are not determinable from the case caption alone.

How this is usually structured in Salix’s Hatch-Waxman suits

• Salix’s complaints in this category generally assert Orange Book-listed patents covering at least one of the following:
  1. Drug substance or composition claims
  2. Formulation or tablet/capsule composition claims
  3. Method-of-use claims (including dosing regimens or indications)
  4. Manufacturing or process claims (less common in purely formulation generics)

Where the asserted patents will be specified

• In the complaint’s “Parties” and “Asserted Patents” sections
• In the attached Orange Book identification and alleged infringement counts
• In any later amended complaint, which often adds patents if FDA or Orange Book listings change during litigation

What infringement theory does Salix use (ANDA Paragraph IV structure)?

Answer: Hatch-Waxman complaints in this posture usually allege:

• Direct infringement via the “make, use, sell, offer to sell, or import” statutory provisions tied to an ANDA product
• Induced infringement and/or contributory infringement depending on the claim scope and generic product structure
• Statutory artificial act infringement under 35 U.S.C. § 271(e)(2) if the case is tied to an ANDA filing that includes certifications for Orange Book patents

Common claim categories and how generic defendants attack them

• Composition/formulation claims: invalidity under §102/§103; non-infringement based on different excipients, dissolution profile, coatings, or manufacturing steps
• Method-of-use claims: non-infringement based on labeling carve-outs, differences in therapeutic claims actually instructed by the proposed generic label
• Manufacturing/process claims: invalidity based on prior art processes; non-infringement based on different process parameters

How strong is Salix’s patent estate in this dispute?

Answer: Patent strength cannot be assessed without the asserted patent list and claim scope.

Framework that typically drives outcomes in Salix-generic cases

• Claim breadth: composition and method claims with narrow ranges often face harder invalidity challenges but may have stronger non-infringement paths
• Prior art density: if the formulation uses common excipients and well-known coatings, obviousness challenges may dominate
• Prosecution history: amendments narrowing ranges can reduce infringement risk but may also preserve enforceability
• Device of “known equivalents”: defendants often argue equivalence under obviousness; plaintiffs argue criticality of parameters

Litigation levers

• Early claim construction can decide whether key limitations in formulation composition claims are met
• If multiple patents are asserted, courts sometimes narrow to one or two “surviving” patents for trial, especially after Markman

When does Carnegie risk generic entry if the case is settled or litigated to judgment?

Answer: Entry timing depends on:

• whether Salix’s asserted patents include patents with the latest expiration dates
• whether a 30-month FDA stay applies based on the notice and litigation commencement timing
• whether Salix obtains preliminary or permanent injunctive relief (rare, but possible depending on procedural posture and evidence)

Typical ANDA timing mechanics

• A Paragraph IV notice triggers a 30-month stay from FDA approval if a patent infringement suit is filed within statutory timing windows.
• A settlement can produce an agreed generic launch date that may be later than the earliest patent expiry.
• If patents expire during litigation, courts may find counts moot or limit remedies.

Has there been a Paragraph IV settlement in 2:24-cv-07531?

Answer: Settlement terms and whether a settlement occurred cannot be confirmed from the case caption alone.

What to look for in the docket if a settlement occurred

• Stipulation of dismissal with/without prejudice
• Joint motion to stay pending license compliance terms
• Entry of consent judgments or pay-to-delay style dismissals (structure varies by case)

What FDA pathway and Orange Book status is implicated by this litigation?

Answer: The specific reference drug and the Orange Book patents at issue cannot be determined from the docket number alone.

What is usually implicated

• Salix’s suits most often involve ANDAs for GI and inflammatory agents where Salix holds Orange Book protections.
• Salix often asserts formulation and method-of-use protections tied to:
  • delayed release profiles
  • pH-dependent delivery systems
  • dosing regimens and indication-specific labeling

Which parties are involved, and what are their roles?

Answer: Based on the caption:

• Plaintiff: Salix Pharmaceuticals, Inc.
• Defendant: Carnegie Pharmaceuticals, LLC
• Forum: Northern District of Alabama
• Case number: 2:24-cv-07531

What this indicates about litigation posture

• The plaintiff is the NDA holder or Orange Book patent owner (or has enforcement rights).
• The defendant is positioned as the ANDA filer or ANDA-related entity seeking market entry.

How does this dispute compare to other Salix vs. generic litigation?

Answer: Without the asserted patent list and product identity, a direct comparison by patent-family and claim category cannot be completed.

Common patterns across Salix-generic fights

• Plaintiffs typically assert multiple Orange Book patents spanning composition and method-of-use.
• Defendants usually contest claim construction and factual infringement early, then pivot to invalidity after Markman.

Key damages and remedies exposure for Carnegie if infringement is found

Answer: Monetary exposure depends on:

• patent expiry dates
• market size of the reference product
• whether willfulness is established and whether treble damages apply
• whether injunctive relief is entered

Typical remedies

• Statutory damages to the extent permitted for §271(e)(2)
• In some cases, ongoing royalties or injunctions if the court orders permanent relief

Commercial impact: what revenue is at stake?

Answer: Revenue exposure depends on which Salix product is at issue and its net sales before generic entry. That cannot be identified from the docket caption alone.

What to quantify once the asserted drug is known

• Reference product annual net sales
• generic penetration to date (if any)
• payer mix and tender exposure
• substitution rates once approval occurs

Key Takeaways

• The case Salix Pharmaceuticals, Inc. v. Carnegie Pharmaceuticals, LLC (2:24-cv-07531) is a 2024 Hatch-Waxman-style infringement dispute in the Northern District of Alabama.
• Specific asserted patents, claims at issue, and infringement theories cannot be accurately itemized from the provided docket identifier alone.
• Litigation outcome and generic entry timing will hinge on Orange Book patent expiration dates, claim construction results, and whether any settlement dismissals occur on the docket.

FAQs

1. What does a Salix vs. Carnegie Pharmaceuticals case number in Alabama usually indicate about the FDA certification?
2. How do Orange Book patent expiration dates typically drive whether a Hatch-Waxman case becomes moot?
3. What claim limitations in formulation or method-of-use patents most often survive Markman in ANDA disputes?
4. What settlement signals should be monitored on the docket in Hatch-Waxman cases?
5. How do courts calculate damages exposure under §271(e)(2) when a generic product approval is delayed?

References (APA)

1. Salix Pharmaceuticals, Inc. v. Carnegie Pharmaceuticals, LLC, No. 2:24-cv-07531 (N.D. Ala. filed 2024).